FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385716672> ?p ?o ?g. }

• W4385716672 endingPage "2947" @default.
• W4385716672 startingPage "2938" @default.
• W4385716672 abstract "Integrin receptors have long posed as a potentially attractive target for disrupting cancer hallmarks. Promising preliminary findings with integrin inhibition as an adjuvant to chemotherapy have not translated to clinical success. However, the effect of integrin inhibition on tumor-immune cell interactions remains largely unexplored. Further investigation could shed light on a connection between integrin signaling and immune checkpoint expression, opening the path for using integrin inhibitors to sensitize otherwise resistant tumors to immunotherapy. Fluorescently labeled wild-type HCT-116 colorectal cancer cells and TALL-104 T-cells were co-cultured and treated with GLPG-0187, a small molecule integrin inhibitor, at various doses. This assay revealed dose dependent cancer cell killing, indicating that integrin inhibition may be sensitizing cancer cells to immune cells. The hypothesized mechanism involves TGF-β-mediated PD-L1 upregulation in cancer cells. To investigate this mechanism, both WT and p53-/- HCT-116 cells were pre-treated with GLPG-0187 and subsequently with latent-TGF-β. Western blot analysis demonstrated that the addition of latent-TGF-β increased the expression of PD-L1 in cancer cells. Additionally, a low dose of integrin inhibitor rescued these effects, returning PD-L1 expression back to control levels. This indicates that the immunostimulatory effects of integrin inhibition may be due to downregulation of immune checkpoint PD-L1 on cancer cells. It must be noted that the higher dose of the drug did not reduce PD-L1 expression. This could potentially be due to off-target effects conflicting with the proposed pathway; however, these findings are still under active investigation. Ongoing proteomic experiments will include a larger range of both drug and latent-TGF-β doses. Probing for additional downstream markers of TGF-β and up-stream markers of PD-L1 will help to further elucidate this mechanism. Further co-culture experiments will also include anti-PD-L1 and anti-PD-1 therapy to investigate the viability of integrin inhibition as an adjuvant to immune checkpoint blockade." @default.
• W4385716672 created "2023-08-11" @default.
• W4385716672 creator A5000711112 @default.
• W4385716672 creator A5029992402 @default.
• W4385716672 creator A5057370803 @default.
• W4385716672 creator A5068051991 @default.
• W4385716672 creator A5075201353 @default.
• W4385716672 creator A5080589878 @default.
• W4385716672 date "2023-01-01" @default.
• W4385716672 modified "2023-09-24" @default.
• W4385716672 title "Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1." @default.
• W4385716672 cites W1983961550 @default.
• W4385716672 cites W2015303690 @default.
• W4385716672 cites W2019905528 @default.
• W4385716672 cites W2030612376 @default.
• W4385716672 cites W2051816002 @default.
• W4385716672 cites W2053415590 @default.
• W4385716672 cites W2071448631 @default.
• W4385716672 cites W2101922439 @default.
• W4385716672 cites W2109578109 @default.
• W4385716672 cites W2136471260 @default.
• W4385716672 cites W2314729200 @default.
• W4385716672 cites W2321845872 @default.
• W4385716672 cites W2399585527 @default.
• W4385716672 cites W2785803176 @default.
• W4385716672 cites W2788975052 @default.
• W4385716672 cites W2889646458 @default.
• W4385716672 cites W2963540928 @default.
• W4385716672 cites W2965867002 @default.
• W4385716672 cites W3110528877 @default.
• W4385716672 cites W3119715349 @default.
• W4385716672 cites W3130224122 @default.
• W4385716672 cites W3153990830 @default.
• W4385716672 cites W4210835170 @default.
• W4385716672 cites W4226440498 @default.
• W4385716672 cites W4237733156 @default.
• W4385716672 cites W4281732693 @default.
• W4385716672 cites W4304585144 @default.
• W4385716672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37559982" @default.
• W4385716672 hasPublicationYear "2023" @default.
• W4385716672 type Work @default.
• W4385716672 citedByCount "0" @default.
• W4385716672 crossrefType "journal-article" @default.
• W4385716672 hasAuthorship W4385716672A5000711112 @default.
• W4385716672 hasAuthorship W4385716672A5029992402 @default.
• W4385716672 hasAuthorship W4385716672A5057370803 @default.
• W4385716672 hasAuthorship W4385716672A5068051991 @default.
• W4385716672 hasAuthorship W4385716672A5075201353 @default.
• W4385716672 hasAuthorship W4385716672A5080589878 @default.
• W4385716672 hasConcept C104317684 @default.
• W4385716672 hasConcept C121608353 @default.
• W4385716672 hasConcept C126322002 @default.
• W4385716672 hasConcept C127561419 @default.
• W4385716672 hasConcept C170493617 @default.
• W4385716672 hasConcept C195687474 @default.
• W4385716672 hasConcept C203014093 @default.
• W4385716672 hasConcept C2777701055 @default.
• W4385716672 hasConcept C502942594 @default.
• W4385716672 hasConcept C526805850 @default.
• W4385716672 hasConcept C55493867 @default.
• W4385716672 hasConcept C71924100 @default.
• W4385716672 hasConcept C86803240 @default.
• W4385716672 hasConcept C8891405 @default.
• W4385716672 hasConcept C96232424 @default.
• W4385716672 hasConceptScore W4385716672C104317684 @default.
• W4385716672 hasConceptScore W4385716672C121608353 @default.
• W4385716672 hasConceptScore W4385716672C126322002 @default.
• W4385716672 hasConceptScore W4385716672C127561419 @default.
• W4385716672 hasConceptScore W4385716672C170493617 @default.
• W4385716672 hasConceptScore W4385716672C195687474 @default.
• W4385716672 hasConceptScore W4385716672C203014093 @default.
• W4385716672 hasConceptScore W4385716672C2777701055 @default.
• W4385716672 hasConceptScore W4385716672C502942594 @default.
• W4385716672 hasConceptScore W4385716672C526805850 @default.
• W4385716672 hasConceptScore W4385716672C55493867 @default.
• W4385716672 hasConceptScore W4385716672C71924100 @default.
• W4385716672 hasConceptScore W4385716672C86803240 @default.
• W4385716672 hasConceptScore W4385716672C8891405 @default.
• W4385716672 hasConceptScore W4385716672C96232424 @default.
• W4385716672 hasIssue "7" @default.
• W4385716672 hasLocation W43857166721 @default.
• W4385716672 hasOpenAccess W4385716672 @default.
• W4385716672 hasPrimaryLocation W43857166721 @default.
• W4385716672 hasRelatedWork W1971298167 @default.
• W4385716672 hasRelatedWork W1996150995 @default.
• W4385716672 hasRelatedWork W2594356097 @default.
• W4385716672 hasRelatedWork W3116400448 @default.
• W4385716672 hasRelatedWork W4220665865 @default.
• W4385716672 hasRelatedWork W4283731173 @default.
• W4385716672 hasRelatedWork W4283836012 @default.
• W4385716672 hasRelatedWork W4291367166 @default.
• W4385716672 hasRelatedWork W4308359949 @default.
• W4385716672 hasRelatedWork W4360983034 @default.
• W4385716672 hasVolume "13" @default.
• W4385716672 isParatext "false" @default.
• W4385716672 isRetracted "false" @default.
• W4385716672 workType "article" @default.